晚期肾细胞癌治疗序列的成本效果分析
该研究采用马尔可夫模型,评估美国国家综合癌症网络指南推荐的五种晚期肾细胞癌一线疗法联合相应二线治疗在 favorable 和 intermediate/poor 风险队列中的成本效果,支付意愿阈值为每质量调整生命年15万美元。favorable 风险组中,帕博利珠单抗联合仑伐替尼后接卡博替尼相较帕博利珠单抗联合阿昔替尼后接卡博替尼的增量成本效果比为每质量调整生命年117625美元;intermediate/poor 风险组中,纳武利尤单抗联合伊匹木单抗后接卡博替尼的增量成本效果比为每质量调整生命年4184美元,且优于所有首选治疗。
要点
- favorable 风险组中,帕博利珠单抗联合仑伐替尼后接卡博替尼与帕博利珠单抗联合阿昔替尼后接卡博替尼均为具成本效果的治疗序列。
- intermediate/poor 风险组中,纳武利尤单抗联合伊匹木单抗后接卡博替尼是最具成本效果的治疗序列,且优于所有首选治疗。
- 研究采用每质量调整生命年15万美元的支付意愿阈值进行成本效果分析。
核心结论
- 在 favorable 风险转移性肾细胞癌患者中,帕博利珠单抗联合仑伐替尼后接卡博替尼以及帕博利珠单抗联合阿昔替尼后接卡博替尼为具成本效果的治疗序列。
- 在 intermediate/poor 风险转移性肾细胞癌患者中,纳武利尤单抗联合伊匹木单抗后接卡博替尼是最具成本效果的治疗序列,且优于所有首选治疗。
研究设计与样本
- 研究构建综合马尔可夫模型,分析美国国家综合癌症网络指南推荐的五种当前一线疗法联合适当二线治疗在 International Metastatic RCC Database Consortium favorable 和 intermediate/poor 风险患者队列中的成本效果。
- 模型估算生命年、质量调整生命年(QALYs)和总累积成本,采用每 QALY 15万美元的支付意愿阈值,并进行单因素和概率敏感性分析。
主要发现
- 在 favorable 风险患者中,帕博利珠单抗联合仑伐替尼后接卡博替尼相较帕博利珠单抗联合阿昔替尼后接卡博替尼增加成本32935美元,获得0.28 QALYs,增量成本效果比(ICER)为每 QALY 117625美元。
- 在 intermediate/poor 风险患者中,纳武利尤单抗联合伊匹木单抗后接卡博替尼相较卡博替尼后接纳武利尤单抗增加成本2252美元,获得0.60 QALYs,ICER 为每 QALY 4184美元。
关键数值与推荐
- 支付意愿阈值为每 QALY 15万美元。
- favorable 风险组中,帕博利珠单抗联合仑伐替尼后接卡博替尼相较帕博利珠单抗联合阿昔替尼后接卡博替尼的 ICER 为每 QALY 117625美元。
- intermediate/poor 风险组中,纳武利尤单抗联合伊匹木单抗后接卡博替尼相较卡博替尼后接纳武利尤单抗的 ICER 为每 QALY 4184美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 局限性包括不同治疗间中位随访时间存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment landscape for metastatic renal cell carcinoma (mRCC) has significantly evolved in recent years. Without direct comparator trials, factors such as cost effectiveness (CE) are important to guide decision-making. OBJECTIVE: To assess the CE of guideline-recommended approved first- and second-line treatment regimens. DESIGN, SETTING, AND PARTICIPANTS: A comprehensive Markov model was developed to analyze the CE of the five current National Comprehensive Cancer Network-recommended first-line therapies with appropriate second-line therapy for patient cohorts with International Metastatic RCC Database Consortium favorable and intermediate/poor risk. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Life years, quality-adjusted life years (QALYs), and total accumulated costs were estimated using a willingness-to-pay threshold of $150 000 per QALY. One-way and probabilistic sensitivity analyses were performed. RESULTS AND LIMITATIONS: In patients with favorable risk, pembrolizumab + lenvatinib followed by cabozantinib added $32 935 in costs and yielded 0.28 QALYs, resulting in an incremental CE ratio (ICER) of $117 625 per QALY in comparison to pembrolizumab + axitinib followed by cabozantinib. In patients with intermediate/poor risk, nivolumab + ipilimumab followed by cabozantinib added $2252 in costs and yielded 0.60 QALYs compared to cabozantinib followed by nivolumab, yielding an ICER of $4184. Limitations include differences in median follow-up duration between treatments. CONCLUSIONS: Pembrolizumab + lenvatinib followed by cabozantinib, and pembrolizumab + axitinib followed by cabozantinib were cost-effective treatment sequences for patients with favorable-risk mRCC. Nivolumab +ipilimumab followed by cabozantinib was the most cost-effective treatment sequence for patients with intermediate-/poor-risk mRCC, dominating all preferred treatments. PATIENT SUMMARY: Because new treatments for kidney cancer have not been compared head to head, comparison of their cost and efficacy can help in making decisions about the best treatments to use first. Our model showed that patients with a favorable risk profile are most likely to benefit from pembrolizumab and lenvatinib or axitinib followed by cabozantinib, while patients with an intermediate or poor risk profile will probably benefit most from nivolumab and ipilimumab followed by cabozantinib.
引用
- Mason NT, Joshi VB, Adashek JJ, et al. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023. PMID: 36797084. doi:10.1016/j.euo.2023.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。